SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study.
Please provide your email address to receive an email when new articles are posted on . Among patients who received implantable cardioverter defibrillator therapy, a subcutaneous vs. transvenous ...
SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...
Please provide your email address to receive an email when new articles are posted on . Transvenous ICD leads are associated with tricuspid regurgitation compared with subcutaneous ICDs. More research ...
Background: Implantable cardioverter defibrillator (ICD) leads are subject to technical failures and the impact of the resulting public advisories on patient welfare is unclear. The psychological ...
A dedicated bipolar implantable cardioverter-defibrillator (ICD) lead for conduction system pacing (CSP) performed well in a first-in-human multicenter study. Placement of the novel UltiSynq CSP ICD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results